ArticleBioorganic & medicinal chemistry2011
Characterization of chemical, radiochemical and optical properties of a dual-labeled MMP-9 targeting peptide.
Article in Bioorganic & medicinal chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 45 citations in OpenAlex.
- Dual-Labeled Small Peptides in Cancer Imaging and Fluorescence-Guided Surgery: Progress and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Recent Progress in Peptide-Based Fluorescent Probes Biomedical Applications: A Review.International journal of nanomedicine · 2025Review
- Modular Synthesis of Peptide-Based Single- and Multimodal Targeted Molecular Imaging Agents.ACS applied bio materials · 2021Article
- An Activatable NIR Fluorescent Rosol for Selectively Imaging Nitroreductase Activity.Sensors and actuators. B, Chemical · 2020Article
- Dual-modal in vivo fluorescence and photoacoustic imaging using a heterodimeric peptide.Chemical communications (Cambridge, England) · 2018Article
- Towards optimized naphthalocyanines as sonochromes for photoacoustic imagingPhotoacoustics · 2018Article
- Development of a Cell-Based Gene Therapy Approach to Selectively Turn Off Bone Formation.Journal of cellular biochemistry · 2017Article
- Novel Linear Peptides with High Affinity to αvβ3 Integrin for Precise Tumor Identification.Theranostics · 2017Article
- Advancing theranostics with tumor-targeting peptides for precision otolaryngology.World journal of otorhinolaryngology - head and neck surgery · 2016Review
- Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent.Scientific reports · 2016Article
- Targeted radionuclide and fluorescence dual-modality imaging of cancer: preclinical advances and clinical translation.Molecular imaging and biology · 2014Review
- Intraoperative imaging-guided cancer surgery: from current fluorescence molecular imaging methods to future multi-modality imaging technology.Theranostics · 2014Review
- Bimodal imaging probes for combined PET and OI: recent developments and future directions for hybrid agent development.BioMed research international · 2014Review
- Prospective of ⁶⁸Ga-radiopharmaceutical development.Theranostics · 2013Review
- Optimization via specific fluorescence brightness of a receptor-targeted probe for optical imaging and positron emission tomography of sentinel lymph nodes.Journal of biomedical optics · 2013Article
- Non-FDG imaging of atherosclerosis: will imaging of MMPs assess plaque vulnerability?Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2012Review
- Dual-labeling strategies for nuclear and fluorescence molecular imaging: a review and analysis.Molecular imaging and biology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Optical imaging possesses similar sensitivity to nuclear imaging and has led to the emergence of multimodal approaches with dual-labeled nuclear/near-infrared (NIR) agents. The growing impact of (68)Ga (t(1/2)=68 min) labeled peptides on preclinical and clinical research offers a promising opportunity to merge the high spatial resolution of NIR imaging with the clinically-accepted positron emission tomography (PET). Previously, dual-labeled agents have been prepared with longer-lived radiometals and showed no detrimental effects on optical properties as a result of radiolabeling. In this study, we selected a peptide (M(2)) that targets MMP-2/9 and is dual-labeled with IRDye 800 CW and (68)Ga. Since (68)Ga chelation typically requires low pH (3.5-4) and elevated heating temperatures (95 °C), we sought to evaluate the impact of (68)Ga labeling on the optical properties of M(2). An efficient method for preparation of (68)Ga-M(2) was developed and reaction conditions were optimized. Stability studies in PBS, DTPA, and serum were performed and high levels of intact agent were evident under each condition. The addition of multiple reporters to a targeting agent adds further complexity to the characterization and validation and thus requires not only testing to ensure the agent is stable chemically and radiochemically, but also optically. Therefore, fluorescence properties were evaluated using a spectrofluorometer as well as by fluorescence detection via HPLC. It was determined that (68)Ga-labeling conditions did not impair the fluorescent properties of the agent. The agent was then used for in vivo imaging in a mouse model of heterotopic ossification (HO) with activated MMP-9 expression as an early biomarker which precedes mineralization. Although (68)Ga-complexation greatly reduced binding affinity of the peptide and negated tracer uptake on PET, NIR imaging showed consistent fluorescent signal that correlated to MMP-9 expression. This attests to the feasibility of using (68)Ga/NIR for dual-labeling of other peptides or small molecules for multimodality molecular imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.